Squamous Non-Small Cell Lung Carcinoma is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Squamous Non-Small Cell Lung Carcinoma have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Squamous Non-Small Cell Lung Carcinoma compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Squamous Non-Small Cell Lung Carcinoma overview
Squamous cell carcinoma (SCC) of the lung, a subtype of non-small cell lung cancer (NSCLC), typically arises centrally in the main airways like the bronchi. This cancer variant is predominantly linked to tobacco smoke, being the primary cause of cellular transformation. Smoking accounts for about 80% of lung cancer cases in men and 90% in women, with SCC showing a particularly strong association with smoking compared to other NSCLC types. Additional risk factors include age, family history, exposure to second-hand smoke, and contact with mineral dust, metal particles, or asbestos.
For a complete picture of PTSR and LoA scores for drugs in Squamous Non-Small Cell Lung Carcinoma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.